華大基因(300676.SZ)擬推第二期員工持股計劃
格隆匯11月18日丨華大基因(300676.SZ)發佈第二期員工持股計劃(草案),本持股計劃擬籌集資金總額上限為11532.4066萬元,以“份”作為認購單位,每份份額為1.00元,合計認購份額不超過11532.4066萬份。具體份額根據實際出資繳款金額確定。
本持股計劃股票來源為公司回購專用證券賬户已回購的華大基因A股普通股股票。本持股計劃持股規模不超過400.0141萬股,約佔本持股計劃草案公吿日公司股本總額41,391.4325萬股的0.9664%。
本持股計劃的參與對象為公司(含子公司)的董事(不含獨立董事)、監事、高級管理人員及領軍業務人員,初始設立時持有人總人數不超過23人(不含預留份額),具體參加人數、名單將根據公司遴選分配及員工實際繳款情況確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.